Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024)

被引：0

作者：

Hartlapp, I. ^{[1
]}

Valta-Seufzer, D. ^{[1
]}

Siveke, J. T. ^{[2
,3
]}

Alguel, H. ^{[4
]}

Goekkurt, E. ^{[5
,6
]}

Siegler, G. ^{[7
]}

Martens, U. M. ^{[8
]}

Waldschmidt, D. ^{[9
]}

Pelzer, U. ^{[10
]}

Fuchs, M. ^{[11
]}

Kullmann, F. ^{[12
]}

Boeck, S. ^{[13
]}

Ettrich, T. J. ^{[14
]}

Held, S. ^{[15
]}

Keller, R. ^{[16
]}

Anger, F. ^{[17
,18
]}

Germer, C. T. ^{[17
,18
]}

Stang, A. ^{[19
]}

Kimmel, B. ^{[1
]}

Heinemann, V. ^{[9
]}

Kunzmann, V. ^{[1
]}

机构：

[1] Univ Hosp Wurzburg, Med Oncol & Comprehens Canc Ctr Mainfranken, Dept Internal Med 2, Wurzburg, Germany

[2] Univ Med Essen, Bridge Inst Expt Tumor Therapy, Dept Med Oncol, Essen, Germany

[3] Univ Med Essen, West German Canc Ctr, Div Solid Tumor Translat Oncol DKTK Partner Site E, DKFZ Heidelberg, Essen, Germany

[4] Tech Univ Munich, Comprehens Canc Ctr Munchen, Sch Med & Hlth, Inst Tumor Metab,Klinikum Rechts Isar, , Bavaria, Munich, Germany

[5] Hamatol Onkol Praxis Eppendorf HOPE, Hamburg, Germany

[6] Univ Canc Ctr Hamburg UCCH, Hamburg, Germany

[7] Paracelsus Med Univ, Dept Internal Med Hematol & Med Oncol 5, Nurnberg, Germany

[8] SLK Clin Heilbronn GmbH, Dept Internal Med 3, Heilbronn, Germany

[9] Univ Hosp Cologne, Dept Gastroenterol & Hepatol, Cologne, Germany

[10] Humboldt Univ, Charite Univ Med Berlin, Freie Univ Berlin, Berlin Inst Hlth,Div Oncol & Hematol,Charite Campu, Berlin, Germany

[11] Munchen Klin Bogenhausen, Clin Gastroenterol Hepatol & GI Oncol, Munich, Germany

[12] Klinikum Weiden, Kliniken Nordoberpfalz AG, Dept Internal Med I, Weiden, Germany

[13] Ludwig Maximilians Univ Grosshadern, Comprehens Canc Ctr, Dept Med Oncol, Munich, Germany

[14] Ulm Univ Hosp, Dept Internal Med 1, Ulm, Germany

[15] ClinAssess GmbH, Dept Biometr, Leverkusen, Germany

[16] AIO Studien gGmbH, Clin Res, Berlin, Germany

[17] Univ Hosp Wurzburg, Dept Gen Visceral Transplantat Vasc & Pediat Surg, Wurzburg, Germany

[18] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken Wurzburg, Wurzburg, Germany

[19] Asklepios Hosp Barmbek, Dept Haematol Oncol & Palliat Care Med, Hamburg, Germany

来源：

ESMO OPEN | 2024年 / 9卷 / 10期

关键词：

D O I：

10.1016/j.esmoop.2024.103705

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 10 条

[1] " Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) " (vol 7, 100552, 2024)
Hartlapp, I.
Valta-Seufzer, D.
Siveke, J. T.
Alguel, H.
Goekkurt, E.
Siegler, G.
Martens, U. M.
Waldschmidt, D.
Pelzer, U.
Fuchs, M.
Kullmann, F.
Boeck, S.
Ettrich, T. J.
Held, S.
Keller, R.
Anger, F.
Germer, C. T.
Stang, A.
Kimmel, B.
Heinemann, V.
Kunzmann, V.
ESMO OPEN, 2024, 9 (05)
[2] Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
Hartlapp, I
Valta-Seufzer, D.
Siveke, J. T.
Algul, H.
Goekkurt, E.
Siegler, G.
Martens, U. M.
Waldschmidt, D.
Pelzer, U.
Fuchs, M.
Kullmann, F.
Boeck, S.
Ettrich, T. J.
Held, S.
Keller, R.
Anger, F.
Germer, C. T.
Stang, A.
Kimmel, B.
Heinemann, V
Kunzmann, V
ESMO OPEN, 2022, 7 (04)
[3] Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
Hartlapp, I.
Valta-Seufzer, D.
Siveke, J.
Alguel, H.
Goekkurt, E.
Siegler, G. M.
Martens, U. M.
Waldschmidt, D.
Pelzer, U.
Fuchs, M.
Kullmann, F.
Boeck, S.
Ettrich, T. J.
Held, S.
Keller, R.
Anger, F.
Germer, C-T.
Stang, H. A.
Heinemann, V.
Kunzmann, V.
ANNALS OF ONCOLOGY, 2021, 32 : S1091 - S1091
[4] Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113)
Guggenberger, KV.
Bley, TA.
Held, S.
Keller, R.
Flemming, S.
Wiegering, A.
Germer, CT.
Kimmel, B.
Kunzmann, V.
Hartlapp, I.
Anger, F.
EUROPEAN JOURNAL OF RADIOLOGY, 2023, 163
[5] Induction Chemotherapy in Locally Advanced Pancreatic Cancer (LAPC) - Final Results of a Multicenter Randomized Phase 2 AIO Trial (NEOLAP)
Hartlapp, Ingo
Alguel, Hana
Goekkurt, Eray
Siegler, Gabriele
Martens, Uwe
Waldschmidt, Dirk
Pelzer, Uwe
Hennes, Elke
Fuchs, Martin
Siveke, Jens
Kullmann, Frank
Boeck, Stefan
Ettrich, Thomas J.
Ferenczy, Peter
Keller, Ralph
Germer, Christoph-Thomas
Stein, Hubert
Klein, Ingo
Heinemann, Volker
Kunzmann, Volker
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 63 - 63
[6] Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Kunzmann, Volker
Siveke, Jens T.
Alguel, Hana
Goekkurt, Eray
Siegler, Gabriele
Martens, Uwe
Waldschmidt, Dirk
Pelzer, Uwe
Fuchs, Martin
Kullmann, Frank
Boeck, Stefan
Ettrich, Thomas J.
Held, Swantje
Keller, Ralph
Klein, Ingo
Germer, Christoph-Thomas
Stein, Hubert
Friess, Helmut
Bahra, Marcus
Jakobs, Ralf
Hartlapp, Ingo
Heinemann, Volker
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 128 - 138
[7] Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
Kunzmann, V.
Alguel, H.
Goekkurt, E.
Siegler, G. M.
Martens, U. M.
Waldschmidt, D.
Pelzer, U.
Hennes, E.
Fuchs, M.
Siveke, J.
Kullmann, F.
Boeck, S.
Ettrich, T. J.
Ferenczy, P.
Keller, R.
Germer, C-T.
Stein, H.
Hartlapp, I.
Klein, I.
Heinemann, V.
ANNALS OF ONCOLOGY, 2019, 30 : 253 - 253
[8] Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
Michael Haas
Volker Heinemann
Frank Kullmann
Rüdiger P. Laubender
Christina Klose
Christiane J. Bruns
Stefan Holdenrieder
Dominik P. Modest
Christoph Schulz
Stefan Boeck
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 681 - 689
[9] Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
Haas, Michael
Heinemann, Volker
Kullmann, Frank
Laubender, Ruediger P.
Klose, Christina
Bruns, Christiane J.
Holdenrieder, Stefan
Modest, Dominik P.
Schulz, Christoph
Boeck, Stefan
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) : 681 - 689
[10] Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).
Kunzmann, Volker
Martens, Uwe Marc
Alguel, Hana
Siveke, Jens T.
Goekkurt, Eray
Pelzer, Uwe
Siegler, Gabriele Margareta
Hennes, Elke
Waldschmidt, Dirk
Jakobs, Ralf
Ferenczy, Peter
Keller, Ralph
Boeck, Stefan Hubert
Kullmann, Frank
Kapp, Markus
Germer, Christoph Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)

← 1 →